Anti-VEGFs (Formulary)

Important: Formulation and dosage details

Formulation:

Solution for intravitreal injection 40mg/ml (4mg/0·1ml) providing a 2mg dose (Restricted: hospital use only)

Dosage:

See per SMC:

• 857/13: in adults for the treatment of neovascular (wet) age-related macular degeneration. 
• 954/14: for adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion. 
• 1003/14: for adults for the treatment of visual impairment due to diabetic macular oedema (DMO).  SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.
• 1074/15: for adults for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion.

Important: Formulation and dosage details

Formulation:

Solution for intravitreal injection 114.3mg/mL (30.1mg/263microlitres) providing an 8mg dose in 70microlitres (Restricted: hospital use only)

Dosage:

As per SMC:

• 857/13: in adults for the treatment of neovascular (wet) age-related macular degeneration. 
• 954/14: for adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion. 
• 1003/14: for adults for the treatment of visual impairment due to diabetic macular oedema (DMO).  SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline. 

In NHS Highland place in therapy is:

• Poor/short-lived response to current anti-VEGF treatment of aflibercept 2mg or other anti-VEGF within reason eg requiring injections more frequently than 8 weeks.
• Struggling with 8 weekly injections eg due to living far away/transport issues/anxiety.

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 25mg/mL (Restricted: hospital use only)

Dosage:

As per SMC 878/13: in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

Important: Formulation and dosage details

Formulation:

Intravitreal injection, pre-filled syringe 5mg/0·2mL unlicensed (Restricted: specialist use only)

Dosage:

For neo-vascular (wet) age-related macular degeneration.

Important: Formulation and dosage details

Formulation:

Solution for injection 120mg/ml in pre-filled syringe (Restricted: specialist use only)

Dosage:

As per SMC 2272: in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Important: Formulation and dosage details

Formulation:

Solution for injection 120mg/mL (providing a dose of 6mg) (Restricted: hospital use only)

Dosage:

As per SMC 2499: For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO).
SMC restriction: treatment of visual impairment due to DMO in adults with best corrected
visual acuity (BCVA) of 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less
at baseline. 

and SMC 2512: for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD).

Important: Formulation and dosage details

Formulation:

Pre-filled syringes 120mg/mL (providing a dose of 6mg) (Restricted: hospital use only)

Dosage:

As per SMC 2499: For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO).
SMC restriction: treatment of visual impairment due to DMO in adults with best corrected
visual acuity (BCVA) of 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less
at baseline. 

and SMC 2512: for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD).

Important: Formulation and dosage details

Formulation:

Solution for intravitreal injection 1·65mg/0·165mL prefilled syringe, 2·3mg/0·23mL vial (Restricted: specialist use only)